Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01753713 · ClinicalTrials.gov registry record · Phase 2
Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
A Phase 2 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, sponsored by Manmeet Ahluwalia, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT01753713: Completed Phase 2 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, sponsored by Manmeet Ahluwalia, MD.
NCT01753713 is a Phase 2 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma that has completed, run by Manmeet Ahluwalia, MD. The registered enrollment target is 33 participants, below the 41-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target (20% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01753713, a Phase 2 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, has completed, sponsored by Manmeet Ahluwalia, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well dovitinib works in treating patients with recurrent or progressive glioblastoma. Dovitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Primary Outcome
Number of anti-angiogenic therapy (including anti-VEGF therapy or bevacizumab) naive patients with recurrent glioblastoma (GBM). The progression- free survival (PFS) at 6 months is defined as the time from randomization to objective tumor progression or death. So patients who have CR, PR or SD at 6 months will constitute PFS-6. Progression is defined using the Response Assessment in Neuro-Oncology (RANO) Criteria where CR = Total disappearance of lesions, PR = \>50% reduction in lesions and SD =
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG dovitinib
Study Locations (1)
Ohio
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2012-12-20 |
| Est. Completion | 2017-09-20 |
| Phase | Phase 2 |
What the finished NCT01753713 record still lists
NCT01753713 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 41-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target (20% lower).
The record links to 4 conditions, with Adult Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01753713 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT01753713 about?
NCT01753713 is a clinical study titled "Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma". This phase II trial studies how well dovitinib works in treating patients with recurrent or progressive glioblastoma. Dovitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
What is the current status of trial NCT01753713?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2012-12-20. Estimated completion is 2017-09-20.
What conditions does trial NCT01753713 study?
This clinical trial studies the following conditions: Adult Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor.
What interventions are being tested in trial NCT01753713?
The interventions under investigation include: laboratory biomarker analysis (OTHER), dovitinib (DRUG).
Who is sponsoring clinical trial NCT01753713?
This trial is sponsored by Manmeet Ahluwalia, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01753713 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01753713's enrollment target sits among peer trials
33 7th of 14 higher than 8 of 14 other Adult Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adult Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
COMPLETED · Phase 2
-
Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
COMPLETED · Phase 2
-
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
ACTIVE NOT RECRUITING · Phase 1
-
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
ACTIVE NOT RECRUITING · Phase 1
-
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI